Our Technology

Monoclonal antibodies and related products

Recombinant proteins are major advancements in targeted therapies and monoclonal antibodies are the spearhead of this industry.

Tailor-made

Recognition Specificity

High Bioavailability

Long Half-Life

Limited Side Effects

Spaced Injections

Species Specific

Therapeutic nucleic acids

Thanks to the latest advances in drug vectorization, it is now possible to make the body produce its own therapeutic proteins, drastically reducing their production cost and improve the posology.

Harfang is proud to work with these revolutionary molecules that will soon change the veterinary pharmacology.

Drug Devices Combination (DDC)

The drug administration device can be of great importance because it will determine the pharmacokinetic parameters of the drug (Tmax, Cmax, AUC, t1/2, MRT, etc…) and also allow access to its target to provide the best drug expected therapeutic effect.

It also may influence the dosage regimen and cost of treatment. The drug administration device is a medical device that must meet the safety and performance requirements set out in current regulations.

We are able to make the best choice for our candidate as well to give you the best advice and assistance in this area, both technically and from a regulatory perspective.